The global colorectal cancer screening market size was valued at USD 16.1 billion in 2025 and is projected to grow from USD 17.39 billion in 2026 to USD 32.18 billion by 2034, registering a CAGR of 8% during the forecast period from 2026 to 2034. North America dominated the colorectal cancer screening market with a market share of 38.4% in 2025.
Colorectal cancer screening includes tests and procedures used to detect colorectal cancer or precancerous changes before symptoms appear. Common methods include colonoscopy, stool-based tests, sigmoidoscopy, and imaging techniques. Screening helps identify the disease at an earlier stage when treatment can be more effective. Demand is growing due to rising colorectal cancer cases, greater awareness of early detection, and expanding screening programs.
Download a Free Sample To learn more about this report,
Growing Adoption of Non-Invasive and At-Home Screening Tests
Colorectal cancer screening market trends are being driven by increasing demand for convenient and non-invasive screening methods that can improve participation among eligible adults. Stool-based tests, including fecal immunochemical tests and multi-target stool DNA tests, allow people to collect samples at home without undergoing an initial colonoscopy. Healthcare providers are increasingly using these options to reach individuals who may avoid traditional screening because of preparation requirements, cost, or inconvenience. Growing awareness of early cancer detection is further supporting adoption. These developments are supporting colorectal cancer screening market growth as healthcare systems focus on improving screening rates.
Rising Development of Blood-Based Colorectal Cancer Screening
Blood-based screening is emerging as an important area of innovation because a routine blood draw may provide a more convenient option for individuals who do not complete stool-based testing or colonoscopy. Developers are using advanced molecular technologies to identify cancer-associated signals in circulating DNA, while research continues to improve sensitivity for earlier-stage disease. Integration of these tests into routine clinical workflows could help expand screening participation. These developments are strengthening colorectal cancer screening market share by creating additional screening choices alongside colonoscopy and stool-based methods.
Growing Awareness of Early Colorectal Cancer Detection
The colorectal cancer screening market is growing steadily as healthcare providers emphasize early detection to identify cancer and precancerous abnormalities before symptoms become severe. Colonoscopy, stool-based tests, imaging techniques, and molecular screening methods provide different options for people based on age and risk factors. Expanding screening programs and greater public awareness of preventive healthcare are strengthening colorectal cancer screening market demand worldwide.
Low Screening Participation and Invasive Procedure Concerns
The colorectal cancer screening market faces restraints because some individuals avoid screening due to discomfort, bowel preparation requirements, fear of invasive procedures, or limited awareness. Colonoscopy can also require specialized facilities and trained professionals, increasing costs and limiting accessibility in underserved regions. These factors can contribute to lower screening participation among eligible populations.
Rising Adoption of Non-Invasive and Molecular Screening Tests
The colorectal cancer screening market offers strong opportunities as blood-based tests, stool DNA testing, and other molecular diagnostic technologies continue to advance. Convenient non-invasive options can potentially improve screening participation while helping identify individuals who require further diagnostic evaluation. Growing investment in precision diagnostics and home-based testing is expected to strengthen colorectal cancer screening market share over the coming years.
Maintaining Test Accuracy and Ensuring Follow-Up Diagnosis
The colorectal cancer screening market continues to face challenges in achieving reliable sensitivity and specificity across different screening methods. Positive results from non-invasive tests generally require follow-up diagnostic evaluation, making patient compliance important throughout the screening pathway. Healthcare systems must also manage testing capacity, accessibility, and appropriate screening intervals.
Colonoscopy Segment Dominated the Market with 46.7% Share in 2025
The colonoscopy segment dominated the global colorectal cancer screening market with a 46.7% share in 2025. Colonoscopy is widely used for colorectal cancer screening because it allows healthcare professionals to examine the entire colon and identify suspicious growths or polyps. It also enables the removal of certain polyps during the same procedure, supporting its established role in screening programs.
Stool-based tests accounted for 35.8% and are growing at the highest CAGR of 6.9%. Their non-invasive nature, convenience, and suitability for at-home sample collection are supporting wider adoption. CT colonography provides a less invasive imaging-based screening option, while flexible sigmoidoscopy is used to examine the lower portion of the colon. Increasing awareness and screening participation are supporting colorectal cancer screening market growth across different test types.
Request Customizationto receive a tailored report.
Hospitals and Clinics Segment Dominated the Market with 61.5% Share in 2025
The hospitals and clinics segment dominated the global colorectal cancer screening market with a 61.5% share in 2025. These healthcare facilities perform a large number of screening and diagnostic procedures and provide access to gastroenterologists, imaging systems, laboratories, and other supporting medical infrastructure. Their ability to provide screening, diagnosis, and follow-up care continues to strengthen the segment's leading position.
Diagnostic imaging centres accounted for 27.8% and are growing at the highest CAGR of 6.6%. Increasing availability of advanced imaging technologies and growing use of CT colonography are supporting demand through these facilities.
Other end users accounted for 10.7% and contribute through specialized screening and diagnostic services. Expanding access to screening facilities is supporting colorectal cancer screening market demand.
Speak to an Analystto discuss market opportunities.
North America colorectal cancer screening market accounted for 38.4% of the global market, reaching USD 6.18 billion in 2025, and is projected to grow at a CAGR of 5.2% during the forecast period. Strong healthcare infrastructure, established cancer screening programs, and increasing awareness of early colorectal cancer detection are supporting regional demand. Growing adoption of colonoscopy, stool-based tests, and advanced non-invasive screening methods is further improving screening participation.
The US market was valued at USD 5.25 billion in 2025, making it the largest contributor in North America. Established screening programs, advanced diagnostic infrastructure, and increasing adoption of stool-based and minimally invasive testing methods continue to support market growth.
Canada's market reached USD 0.93 billion in 2025. Organized screening programs, increasing awareness of early diagnosis, and improved access to colorectal cancer testing are supporting market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe colorectal cancer screening market accounted for 29.1% of the global market, reaching USD 4.69 billion in 2025, and is expected to register a CAGR of 5.5% during the forecast period. Government-supported screening initiatives, aging populations, and growing awareness of colorectal cancer prevention are supporting regional demand. Increasing adoption of fecal immunochemical tests and colonoscopy-based screening is also improving early detection rates.
Germany's market accounted for USD 1.36 billion in 2025. Established cancer screening programs, advanced healthcare infrastructure, and increasing focus on preventive healthcare continue to support market growth.
The UK market was valued at USD 0.94 billion in 2025. Organized bowel cancer screening programs, increasing public awareness, and wider availability of home-based screening tests continue to contribute to market development.
Asia Pacific colorectal cancer screening market accounted for 22.3% of the global market, reaching USD 3.59 billion in 2025, and is projected to register the fastest regional CAGR of 7.4% during the forecast period. Improving healthcare infrastructure, increasing awareness of cancer prevention, aging populations, and expansion of screening programs are driving regional demand. Greater availability of non-invasive diagnostic tests is also encouraging participation in colorectal cancer screening.
Japan's market generated USD 0.65 billion in 2025. An aging population, established healthcare infrastructure, and strong focus on preventive cancer screening continue to support demand for colorectal cancer testing.
China's market accounted for USD 1.87 billion in 2025, making it a major contributor within Asia Pacific. Expanding healthcare access, increasing colorectal cancer awareness, growing screening initiatives, and adoption of advanced diagnostic technologies continue to drive market growth.
Middle East & Africa colorectal cancer screening market accounted for 4.1% of the global market, reaching USD 0.66 billion in 2025, and is anticipated to grow at a CAGR of 5.9% during the forecast period. Improving healthcare infrastructure, increasing cancer awareness, and growing investment in diagnostic services are supporting regional development.
The UAE market was valued at USD 0.24 billion in 2025. Advanced healthcare facilities, increasing preventive health initiatives, and greater awareness of early colorectal cancer detection continue to support screening adoption.
The global Colorectal Cancer Screening market is highly competitive, driven by growing awareness of early cancer detection, increasing screening programs, and rising adoption of non-invasive diagnostic methods. Key players include Exact Sciences Corp., Danaher Corp., DiaCarta, Eiken Chemical Co., Ltd., Freenome Holdings Inc., Fujifilm Holdings Corp., GI-View, Guardant Health, Hangzhou Novahealth Technology Co., Ltd., Laboratory Corporation of America Holdings, Lepu Medical Technology (Beijing) Co., Ltd., Mainz Biomed N.V., Novigenix SA, Olympus Corp., Quest Diagnostics Inc., and QuidelOrtho Corp. Companies are focusing on stool-based tests, blood-based screening, molecular diagnostics, advanced imaging, and AI-supported technologies to improve early detection and patient convenience.
Exact Sciences Corp.: An Emerging Market Leader
Exact Sciences has strengthened its position through its non-invasive colorectal cancer screening and molecular diagnostic solutions. The company focuses on improving early cancer detection, increasing screening accessibility, and developing convenient testing options that encourage greater patient participation. These capabilities support Exact Sciences’ strong position in the global colorectal cancer screening market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Cryotherapy Market Size, Share, Growth, Analysis, Report, 2034
Spinal Cord Stimulation Market Size, Share, Growth, Analysis, 2034
Personal Mobility Devices Market Size, Share, Growth, Analysis, 2034
Medical Waste Containers Market Size, Share, Growth, Analysis, 2034
Hemostasis & Tissue Sealing Agents Market Size, Share, 2034
Assisted Walking Devices Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com